Page last updated: 2024-11-07

6-hydroxydopa

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-hydroxydopa is a dopamine analog that has been studied for its potential therapeutic effects in neurodegenerative diseases. It is synthesized through the enzymatic hydroxylation of dopa by tyrosine hydroxylase. Research suggests that 6-hydroxydopa may exhibit neuroprotective properties by reducing oxidative stress and inhibiting the aggregation of alpha-synuclein, a protein implicated in Parkinson's disease. Additionally, studies have indicated that 6-hydroxydopa may act as a substrate for dopamine synthesis, potentially enhancing dopamine levels in the brain. The potential therapeutic benefits of 6-hydroxydopa in conditions like Parkinson's disease and Alzheimer's disease have fueled ongoing research efforts to understand its mechanisms of action and explore its clinical applications.'

6-hydroxydopa: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107794
CHEMBL ID109037
CHEBI ID20725
SCHEMBL ID503251
MeSH IDM0041557

Synonyms (67)

Synonym
6-hydroxydopa
H2380
EU-0100633
6-hydroxy-dl-dopa, >=98% (tlc), powder
LOPAC0_000633
6-hydroxy-dl-dopa
NCGC00094000-01
NCGC00094000-02
3,4,6-topa
CHEBI:20725 ,
2,5-dihydroxytyrosine
smr000326920
6-ohdopa
MLS002153447 ,
2-amino-3-(2,4,5-trihydroxyphenyl)propanoic acid
3,4,6-trihydroxyphenylalanine
2,4,5-trihydroxyphenylalanine
21373-30-8
NCGC00015503-02
2,5-dihydroxy-dl-tyrosine
H 2380
NCGC00015503-06
CHEMBL109037 ,
23358-64-7
AKOS003382703
FT-0669564
SR-01000075906-8
SR-01000075906-7
sr-01000075906
HMS3261P08
2,4,5-trihydroxyphenyl-d,l-alanine
CCG-204721
NCGC00015503-04
NCGC00015503-03
NCGC00015503-05
unii-9hbl9xyq8o
tyrosine, 2,5-dihydroxy-
9hbl9xyq8o ,
6-hydroxy-dopa
2,4,5-trihydroxy-dl-phenylalanine
FT-0638316
LP00633
bdbm50436204
3-(3,4,6-trihydroxyphenyl)alanine
dl-topa
3,4,6-trihydroxy-dl-phenylalanine
6-hydroxydopa, dl-
3-(2,4,5-trihydroxyphenyl)-dl-alanine
dl-tyrosine, 2,5-dihydroxy-
dl-6-hydroxydopa
NCGC00261318-01
tox21_500633
SCHEMBL503251
W-201873
J-015084
SR-01000075906-1
6-hydroxy-d,l-dopa
DTXSID00943928
Q27109347
SDCCGSBI-0050614.P002
NCGC00015503-08
2-amino-3-(2,4,5-trihydroxyphenyl)propanoicacid
HY-110286
6-hydroxydopa crystalline
PB47574
CS-0033154
PD015276

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Solutions of TOPA were also toxic to mesencephalic neurons after acute or chronic exposure, displaying the same leftward shift in LD50."( Characterization of 2,4,5-trihydroxyphenylalanine neurotoxicity in vitro and protective effects of ganglioside GM1: implications for Parkinson's disease.
Dal Toso, R; Facci, L; Leon, A; Moroni, F; Schiavo, N; Skaper, SD; Vantini, G, 1992
)
0.28
" In addition, 2 mM GSH protected neurons from the toxic effects of 200 microM TOPA, but was not effective against 200 microM NMDA."( Glutathione prevents 2,4,5-trihydroxyphenylalanine excitotoxicity by maintaining it in a reduced, non-active form.
Aizenman, E; Boeckman, FA; Rosenberg, PA, 1992
)
0.28

Pharmacokinetics

ExcerptReferenceRelevance
" Study of pharmacokinetic parameters (AUC, C(max), and T(max)) revealed a greater and more extended release of ropinirole from nanoemulsion gel compared to that from a conventional gel (RPG) and oral marketed tablet (Ropitor)."( Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation.
Ahmad, FJ; Azeem, A; Iqbal, Z; Khar, RK; Negi, LM; Talegaonkar, S, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
"Ropinirole, a recent introduction in the clinical treatment of Parkinson's disease, suffers with the problems of low oral bioavailability and frequent dosing."( Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation.
Ahmad, FJ; Azeem, A; Iqbal, Z; Khar, RK; Negi, LM; Talegaonkar, S, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" Application of solutions of TOPA to cerebellar granule cells resulted in a concentration- and time-dependent neuronal death, with prolonged (24 hr) exposure producing a clear left-handed shift in the dose-response relationship from the one observed with a 60-min exposure (LD50: 4 and 29 microM, respectively)."( Characterization of 2,4,5-trihydroxyphenylalanine neurotoxicity in vitro and protective effects of ganglioside GM1: implications for Parkinson's disease.
Dal Toso, R; Facci, L; Leon, A; Moroni, F; Schiavo, N; Skaper, SD; Vantini, G, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
non-proteinogenic alpha-amino acidAny alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (57)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.28470.003245.467312,589.2998AID1705; AID2517; AID2572
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency2.32230.004023.8416100.0000AID485290; AID489007
Chain A, Beta-lactamaseEscherichia coli K-12Potency28.59910.044717.8581100.0000AID485294; AID485341
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency12.58930.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency15.57060.125919.1169125.8920AID2353; AID2549; AID2708
Chain A, Ferritin light chainEquus caballus (horse)Potency19.95265.623417.292931.6228AID2323
Chain A, CruzipainTrypanosoma cruziPotency25.11890.002014.677939.8107AID1478
endonuclease IVEscherichia coliPotency31.62280.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency27.64480.100020.879379.4328AID488773; AID588453
USP1 protein, partialHomo sapiens (human)Potency12.95870.031637.5844354.8130AID504865; AID540327
GLS proteinHomo sapiens (human)Potency1.25890.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency5.66070.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency15.95410.180013.557439.8107AID1460; AID1468
thioredoxin glutathione reductaseSchistosoma mansoniPotency15.84890.100022.9075100.0000AID485364
DNA polymerase III, partialBacillus subtilisPotency4.74441.062114.152826.6795AID485295
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency11.22020.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency2.99350.531815.435837.6858AID504845
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency8.91250.28189.721235.4813AID2326
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency4.74620.001530.607315,848.9004AID1224819; AID1224820
luciferasePhoturis pensylvanica (Pennsylania firefly)Potency11.22020.891310.432820.5750AID1379
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency0.89130.707936.904389.1251AID504333
arylsulfatase AHomo sapiens (human)Potency16.94411.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.03940.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency3.16230.540617.639296.1227AID2364; AID2528
hexokinase-4 isoform 1Homo sapiens (human)Potency35.48132.511913.800328.1838AID743207
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency4.46680.001815.663839.8107AID894
runt-related transcription factor 1 isoform AML1bHomo sapiens (human)Potency6.25590.02007.985839.8107AID504374; AID504375
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency0.31620.006026.168889.1251AID488953
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency11.22020.010039.53711,122.0200AID1479
glucokinase regulatory proteinHomo sapiens (human)Potency35.48132.511913.800328.1838AID743207
core-binding factor subunit beta isoform 2Homo sapiens (human)Potency6.25590.02007.985839.8107AID504374; AID504375
DNA polymerase betaHomo sapiens (human)Potency0.11220.022421.010289.1251AID485314
flap endonuclease 1Homo sapiens (human)Potency1.50090.133725.412989.1251AID488816; AID588795
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency14.41990.65619.452025.1189AID463106; AID463254
eyes absent homolog 2 isoform aHomo sapiens (human)Potency2.39381.199814.641950.1187AID720540
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency31.62280.010323.856763.0957AID2662
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency1.69440.425612.059128.1838AID504536
DNA polymerase eta isoform 1Homo sapiens (human)Potency0.28180.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency0.76000.050127.073689.1251AID588590
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency0.15850.075215.225339.8107AID485360
DNA polymerase kappa isoform 1Homo sapiens (human)Potency1.04140.031622.3146100.0000AID588579
M-phase phosphoprotein 8Homo sapiens (human)Potency0.48780.177824.735279.4328AID488949
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency6.61020.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency25.11890.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency5.01190.015812.3113615.5000AID1461
Glutamate receptor 1Rattus norvegicus (Norway rat)Potency0.79430.01418.602439.8107AID2572
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.79430.001551.739315,848.9004AID2572
Glutamate receptor 3Rattus norvegicus (Norway rat)Potency0.79430.01418.602439.8107AID2572
Glutamate receptor 4Rattus norvegicus (Norway rat)Potency0.79430.01418.602439.8107AID2572
C-terminal-binding protein 1Homo sapiens (human)Potency21.33490.30149.321019.0148AID720541
phosphoglycerate kinaseTrypanosoma brucei brucei TREU927Potency0.33810.07578.474229.0628AID504547
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.50930.060110.745337.9330AID485367; AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)IC50 (µMol)0.11000.05502.967710.0000AID1167344; AID1370986
DNA repair protein RAD52 homologHomo sapiens (human)IC50 (µMol)1.10000.25502.63016.7000AID1743764
Bile acid receptorHomo sapiens (human)IC50 (µMol)7.92000.01834.560310.0000AID755454
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (75)

Processvia Protein(s)Taxonomy
telomere maintenanceDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA repairDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
base-excision repairDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
base-excision repair, gap-fillingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA catabolic processDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA recombinationDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
regulation of apoptotic processDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
regulation of mRNA stabilityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
positive regulation of gene expression via chromosomal CpG island demethylationDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
cell redox homeostasisDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
negative regulation of DNA-templated transcriptionDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
telomere maintenance via base-excision repairDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA double-strand break processing involved in repair via single-strand annealingDNA repair protein RAD52 homologHomo sapiens (human)
cellular response to oxidative stressDNA repair protein RAD52 homologHomo sapiens (human)
regulation of nucleotide-excision repairDNA repair protein RAD52 homologHomo sapiens (human)
DNA recombinase assemblyDNA repair protein RAD52 homologHomo sapiens (human)
double-strand break repairDNA repair protein RAD52 homologHomo sapiens (human)
DNA recombinationDNA repair protein RAD52 homologHomo sapiens (human)
double-strand break repair via homologous recombinationDNA repair protein RAD52 homologHomo sapiens (human)
mitotic recombinationDNA repair protein RAD52 homologHomo sapiens (human)
double-strand break repair via single-strand annealingDNA repair protein RAD52 homologHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIC-terminal-binding protein 1Homo sapiens (human)
protein phosphorylationC-terminal-binding protein 1Homo sapiens (human)
negative regulation of cell population proliferationC-terminal-binding protein 1Homo sapiens (human)
viral genome replicationC-terminal-binding protein 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionC-terminal-binding protein 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionC-terminal-binding protein 1Homo sapiens (human)
synaptic vesicle endocytosisC-terminal-binding protein 1Homo sapiens (human)
white fat cell differentiationC-terminal-binding protein 1Homo sapiens (human)
regulation of cell cycleC-terminal-binding protein 1Homo sapiens (human)
synaptic vesicle clusteringC-terminal-binding protein 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIC-terminal-binding protein 1Homo sapiens (human)
negative regulation of very-low-density lipoprotein particle remodelingBile acid receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionBile acid receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
nitrogen catabolite activation of transcription from RNA polymerase II promoterBile acid receptorHomo sapiens (human)
intracellular glucose homeostasisBile acid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
inflammatory responseBile acid receptorHomo sapiens (human)
cell-cell junction assemblyBile acid receptorHomo sapiens (human)
Notch signaling pathwayBile acid receptorHomo sapiens (human)
bile acid metabolic processBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayBile acid receptorHomo sapiens (human)
regulation of low-density lipoprotein particle clearanceBile acid receptorHomo sapiens (human)
intracellular receptor signaling pathwayBile acid receptorHomo sapiens (human)
negative regulation of type II interferon productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-1 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-2 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-6 productionBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor productionBile acid receptorHomo sapiens (human)
positive regulation of interleukin-17 productionBile acid receptorHomo sapiens (human)
toll-like receptor 9 signaling pathwayBile acid receptorHomo sapiens (human)
regulation of urea metabolic processBile acid receptorHomo sapiens (human)
intracellular triglyceride homeostasisBile acid receptorHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
bile acid signaling pathwayBile acid receptorHomo sapiens (human)
intracellular bile acid receptor signaling pathwayBile acid receptorHomo sapiens (human)
cholesterol homeostasisBile acid receptorHomo sapiens (human)
defense response to bacteriumBile acid receptorHomo sapiens (human)
negative regulation of apoptotic processBile acid receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionBile acid receptorHomo sapiens (human)
innate immune responseBile acid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayBile acid receptorHomo sapiens (human)
fatty acid homeostasisBile acid receptorHomo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
regulation of bile acid biosynthetic processBile acid receptorHomo sapiens (human)
cellular response to lipopolysaccharideBile acid receptorHomo sapiens (human)
cellular response to fatty acidBile acid receptorHomo sapiens (human)
cellular response to organonitrogen compoundBile acid receptorHomo sapiens (human)
negative regulation of monocyte chemotactic protein-1 productionBile acid receptorHomo sapiens (human)
regulation of cholesterol metabolic processBile acid receptorHomo sapiens (human)
cellular response to bile acidBile acid receptorHomo sapiens (human)
positive regulation of adipose tissue developmentBile acid receptorHomo sapiens (human)
positive regulation of phosphatidic acid biosynthetic processBile acid receptorHomo sapiens (human)
positive regulation of glutamate metabolic processBile acid receptorHomo sapiens (human)
positive regulation of ammonia assimilation cycleBile acid receptorHomo sapiens (human)
cell differentiationBile acid receptorHomo sapiens (human)
negative regulation of inflammatory responseBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (48)

Processvia Protein(s)Taxonomy
DNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
damaged DNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
double-stranded telomeric DNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
transcription coactivator activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
transcription corepressor activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
RNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA-(apurinic or apyrimidinic site) endonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
endonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA endonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
RNA-DNA hybrid ribonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
phosphodiesterase I activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
uracil DNA N-glycosylase activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
protein bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
phosphoric diester hydrolase activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
3'-5'-DNA exonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
double-stranded DNA exodeoxyribonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
3'-5' exonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
oxidoreductase activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
site-specific endodeoxyribonuclease activity, specific for altered baseDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
chromatin DNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
metal ion bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
class II DNA-(apurinic or apyrimidinic site) endonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
phosphodiesterase activity, acting on 3'-phosphoglycolate-terminated DNA strandsDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA-(abasic site) bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
double-stranded DNA 3'-5' DNA exonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA bindingDNA repair protein RAD52 homologHomo sapiens (human)
single-stranded DNA bindingDNA repair protein RAD52 homologHomo sapiens (human)
protein bindingDNA repair protein RAD52 homologHomo sapiens (human)
identical protein bindingDNA repair protein RAD52 homologHomo sapiens (human)
transcription corepressor bindingC-terminal-binding protein 1Homo sapiens (human)
chromatin bindingC-terminal-binding protein 1Homo sapiens (human)
transcription corepressor activityC-terminal-binding protein 1Homo sapiens (human)
protein bindingC-terminal-binding protein 1Homo sapiens (human)
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptorC-terminal-binding protein 1Homo sapiens (human)
protein domain specific bindingC-terminal-binding protein 1Homo sapiens (human)
identical protein bindingC-terminal-binding protein 1Homo sapiens (human)
NAD bindingC-terminal-binding protein 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingC-terminal-binding protein 1Homo sapiens (human)
DNA-binding transcription factor bindingC-terminal-binding protein 1Homo sapiens (human)
transcription coactivator activityC-terminal-binding protein 1Homo sapiens (human)
transcription coregulator bindingC-terminal-binding protein 1Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
transcription coregulator bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activityBile acid receptorHomo sapiens (human)
nuclear receptor activityBile acid receptorHomo sapiens (human)
protein bindingBile acid receptorHomo sapiens (human)
zinc ion bindingBile acid receptorHomo sapiens (human)
nuclear receptor bindingBile acid receptorHomo sapiens (human)
bile acid bindingBile acid receptorHomo sapiens (human)
bile acid receptor activityBile acid receptorHomo sapiens (human)
sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
nuclear retinoid X receptor bindingBile acid receptorHomo sapiens (human)
chenodeoxycholic acid bindingBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
chromosome, telomeric regionDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nucleusDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nucleoplasmDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nucleolusDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
cytoplasmDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
mitochondrionDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
endoplasmic reticulumDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
centrosomeDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
ribosomeDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nuclear speckDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
perinuclear region of cytoplasmDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nucleusDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nucleusDNA repair protein RAD52 homologHomo sapiens (human)
nucleoplasmDNA repair protein RAD52 homologHomo sapiens (human)
protein-containing complexDNA repair protein RAD52 homologHomo sapiens (human)
protein-DNA complexDNA repair protein RAD52 homologHomo sapiens (human)
nucleusDNA repair protein RAD52 homologHomo sapiens (human)
nucleusC-terminal-binding protein 1Homo sapiens (human)
nucleoplasmC-terminal-binding protein 1Homo sapiens (human)
presynaptic active zone cytoplasmic componentC-terminal-binding protein 1Homo sapiens (human)
glutamatergic synapseC-terminal-binding protein 1Homo sapiens (human)
GABA-ergic synapseC-terminal-binding protein 1Homo sapiens (human)
transcription repressor complexC-terminal-binding protein 1Homo sapiens (human)
nucleusC-terminal-binding protein 1Homo sapiens (human)
nucleoplasmBile acid receptorHomo sapiens (human)
chromatinBile acid receptorHomo sapiens (human)
euchromatinBile acid receptorHomo sapiens (human)
receptor complexBile acid receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexBile acid receptorHomo sapiens (human)
nucleusBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504787Counterscreen for agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3): TR-FRET-based biochemical high throughput assay to identify agonists of the interaction between peroxisome proliferator-activated receptor gamma (PPARg) and nuclear rec2006Assay and drug development technologies, Jun, Volume: 4, Issue:3
Development of the high throughput screening assay for identification of agonists of an orphan nuclear receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID755454Antagonist activity at human GTS-tagged FXR after 20 mins by TR-FRET assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID92626Percent inhibition of specific [3H]AMPA binding to Ionotropic glutamate receptor AMPA in rat brain membranes at compound concentration of 100 uM1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Structure--activity studies for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid receptors: acidic hydroxyphenylalanines.
AID25863Protolysis constant at an ionic strength of 0.1 M; Not determined1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Structure--activity studies for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid receptors: acidic hydroxyphenylalanines.
AID1380103Inhibition of Aspergillus fumigatus AGM12018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Emerging New Targets for the Treatment of Resistant Fungal Infections.
AID1370986Inhibition of human APE1 preincubated for 15 mins followed by substrate addition by HTS assay2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Inhibitors of nuclease and redox activity of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1).
AID1743764Inhibition of FAM-conjugated ssDNA binding to His-tagged wild type RAD52 (unknown origin) expressed in Rosetta2(DE3)/pLysS cells measured after 30 mins by fluorescence polarization assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Synthetic Lethality through the Lens of Medicinal Chemistry.
AID1167344Inhibition of human APE1 after 25 mins by fluorescence assay2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
DNA repair and redox activities and inhibitors of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1): a comparative analysis and their scope and limitations toward anticancer drug development.
AID755445Agonist activity at PXR (unknown origin) expressed in human HepG2 cells assessed as induction of CYP3A4 transactivation after 16 hrs by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID755455Antagonist activity at human GTS-tagged FXR at 15 uM after 20 mins by TR-FRET assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID1743763Inhibition of FAM-conjugated ssDNA binding to His-tagged wild type RAD52 (unknown origin) expressed in Rosetta2(DE3)/pLysS cells measured after 30 mins by high-throughput fluorescence polarization assay relative to control2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Synthetic Lethality through the Lens of Medicinal Chemistry.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (108)

TimeframeStudies, This Drug (%)All Drugs %
pre-199038 (35.19)18.7374
1990's35 (32.41)18.2507
2000's7 (6.48)29.6817
2010's18 (16.67)24.3611
2020's10 (9.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.23 (24.57)
Research Supply Index4.74 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews11 (9.73%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other102 (90.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]